Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Following the news of "entering the market" and "entering the rich" (the rich GEIS index), Jiankangyuan & Lizhu Group received positive news.
Published Time：
2019-05-31
In the early morning of May 25, Beijing time, FTSE Russell, the world's second-largest index company, announced the first batch of A-shares to be included in its index system. This list includes large-cap, mid-cap, and small-cap stocks, with a total of 1097 A-shares selected, including Health and Medicine Group and Lizhu Group.
FTSE Russell is a wholly-owned subsidiary of the London Stock Exchange Group, the world's second-largest index provider. Currently, approximately US\$16 trillion in assets are benchmarked against FTSE Russell indices. The FTSE GEIS index system is divided into two dimensions: market and market capitalization. The market dimension can be further divided into developed markets, emerging markets (further divided into advanced emerging and secondary emerging), and frontier markets. The market capitalization dimension includes large-cap, mid-cap, small-cap, and micro-cap stocks.
It is understood that scale, liquidity, and growth are the main selection criteria for FTSE Russell's "inclusion of A-shares". In March this year, information on the MSCI website showed that Health and Medicine Group and Lizhu Group are expected to be included in the MSCI China constituents. This re-selection for FTSE GEIS is a further recognition of the comprehensive strength of Health and Medicine and Lizhu Group. Such high-quality enterprises that meet national industrial strategies and have good growth potential are likely to be among the main beneficiaries of this "inclusion of A-shares".
FTSE Russell CEO, Mark Makepeace, previously stated that after the completion of the first three steps of the first phase, A-shares will account for 5.57% of FTSE Russell's emerging market weighting. The first phase of "inclusion in FTSE" will bring a net passive fund inflow of US\$10 billion. It is expected that US\$2 billion, US\$4 billion, and US\$4 billion in passive funds will flow in during June 2019, September 2019, and March 2020, respectively.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.